Clinical trial · Interventional
A Clinical Study of 6MW3211 in Patients With Renal Cancer
A Phase 2, Multicenter, Open-Label Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Advanced Clear Cell Renal Cancer
NCT05440045CI-TRIAL-00060385unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 6MW3211 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 6MW3211
- description
- 6MW3211 injection, 30mg/kg
- interventionNames
- Drug: 6MW3211
Primary outcomes (1)
- measure
- ORR
- timeFrame
- up to 24 months
- description
- Objective response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent. * Advanced clear cell renal cancer. * At least one measurable tumor target lesion. * Life expectancy≥3 months. * Suitable organ functions. * Patients who had failed at least one line therapy. * ECOG 0-1. * The samples of tumor tissue should be provided Exclusion Criteria: * Patients who had received anti-tumor therapy/radiotherapy/immunotherapy within 4 weeks. * History of other malignant tumors within 5 years. * Patients with CNS metastasis. * History of active autoimmune diseases. * Patients with poor-controlled systemic diseases after treatment. * Patients with severe infection or requiring antibiotic treatment within 4 weeks before dosing. * Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1 * Patients who had experienced immune-related adverse events (irAE) with grade 3 or above. * Patients who were allergic to any composition of experimental drug. * Subjects with poor treatment compliance. * Pregnant or lactating woman. * Live vaccination within 28 days before first dosing. * History of drug abuse or addiction * Patients with active HBV or HCV, or HIV antibody positive,or Tp-Ab positive.
References
Publications (0)
Data not yet available
No reference posted for this study.